President Obama Addresses Precision Medicine Initiative


From DCAT Value Chain Insights (VCI)

By Regulatory News posted 01-23-2015 16:08

  

In his State of the Union Address on January 20, 2015, President Barack Obama signaled the launch a new effort, the Precision Medicine Initiative, to advance the development of personalized medicines in the United States. While offering few details, the announcement was supported by the Pharmaceutical Research and Manufacturers of America (PhRMA).

"I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes, and to give all of us access to the personalized information we need to keep ourselves and our families healthier," said the President in the address.

President and CEO, John J. Castellani issued a statement supporting the initiative. “We commend the administration’s commitment to advancing the field of precision, or personalized, medicine. The biopharmaceutical research sector is strongly committed to researching and developing personalized medicines, and ensuring patients can gain timely access to them. Recent advances in diseases such as cancer and cystic fibrosis are delivering on the promise of targeted treatments, and between 12 and 50% of all compounds currently being researched by the industry are potential personalized medicines. These advances hold great promise in improving patient outcomes and controlling costs by targeting the right medicines to the right patients. PhRMA is committed to advancing scientific, regulatory, and reimbursement policies that support development of and patient access to personalized medicines and other new treatments, and we look forward to working with the administration, as well as leaders on both sides of the aisle in Congress who are developing reforms in this important area.”

Source: White House and PhRMA

0 comments
37 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink